Perseon Appoints Jennifer R. Hoglin Vice President of Global Marketing
February 26 2015 - 9:15AM
Perseon Corporation (Nasdaq:PRSN) (Perseon or the Company), a
leading provider of medical systems that utilize heat therapy to
treat cancer, today announced the appointment of Jennifer R. Hoglin
as Vice President of Global Marketing, effective February 17, 2015.
Ms. Hoglin is an executive marketing professional with 20 years of
experience in product, brand, and business development experience
in primarily life sciences as well as multiple other industries.
Clint Carnell, CEO of Perseon, commented, "Jennifer is a
consummate life sciences marketing executive and I'm thrilled to
welcome her to our leadership team at Perseon. Her professional
expertise, honed from two decades with early stage to
multi-national companies, is specialized right in the key areas of
focus for Perseon: branding, customer adoption, and peer-to-peer
marketing. Jennifer's new role and the marketing acumen she brings
will be paramount to Perseon's future as we execute our strategic
plan for commercial success in microwave ablation."
Ms. Hoglin's career spans key leadership roles in go-to-market
and commercialization strategy and development, most recently as
Vice President of Marketing at Catheter Connections Inc., a
manufacturer of infection control products. Formerly as Senior
Director of Global Marketing at Edwards Lifesciences, she led
integral marketing efforts involving product portfolio development
and global professional education teams, programs, and tactics.
Earlier she managed strategic marketing for Myriad Genetics
Laboratories' Preventive Care Business, and she has held various
positions with CR Bard and 3M. Ms. Hoglin holds an MBA from
Washington University, St. Louis, MO and a BA from The Colorado
College, Colorado Springs, CO.
About Perseon
Perseon Corporation, formerly BSD Medical Corporation, is a life
sciences company that develops, manufactures, markets and services
groundbreaking medical systems to treat cancer using heat therapy.
Perseon's MicroThermX® microwave ablation system employs
precision-guided microwave energy to ablate (destroy) soft tissue.
The Company has developed extensive intellectual property and
distributes its products in the United States, Europe and Asia.
Forward-Looking Statements
Statements contained in this press release that are not
historical facts, including statements relating to our intent to
divest our hyperthermia business in Spring 2015, focus on microwave
ablation to create stockholder value, comply with Nasdaq continued
listing requirements, generate capital from a transaction related
to our building and pursue other strategic plans are
forward-looking statements, as defined in the Private Securities
Litigation Reform Act of 1995. All forward-looking statements are
subject to risks and uncertainties, including the risk that for a
variety of reasons we may not be able to execute on our strategic
plans, and other risks and uncertainties detailed in the Company's
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date on which such
statements are made, and the Company undertakes no obligation to
update such statements to reflect events or circumstances arising
after such date, except as required by law.
CONTACT: Tricia Ross
Financial Profiles
310-622-8226
tross@finprofiles.com